Johnson & Johnson (NYSE: JNJ) closed Friday at $240.87, gaining 1.07% and outperforming the broader market as the S&P 500 rose 0.50% and the Dow Jones Industrial Average added 0.70%. The healthcare giant's stock is now trading near its 52-week highs, fueled by fresh clinical data that strengthens the bull case for its oncology pipeline.
On Saturday, J&J released Phase 3 MonumenTAL-3 data evaluating Talvey in combination with Darzalex Faspro, with or without pomalidomide, for patients with earlier-line relapsed or refractory multiple myeloma. The results showed that the combination reduced the risk of disease progression or death by up to 72% and cut the risk of death by as much as 53% compared to standard therapy. Progression-free survival at 24 months reached 81.3% versus 51.2% for standard care, while overall survival stood at 89.2% compared to 79.1%.
This data is critical for J&J as its valuation increasingly depends on new drugs compensating for declining sales of older products. In the first quarter, Innovative Medicine sales rose 7.4% operationally, driven by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya, and Spravato. However, Stelara weighed heavily, reducing Innovative Medicine growth by approximately 920 basis points.
The company's bull narrative centers on pipeline depth, with growth and defense both in play. In April, J&J reported first-quarter sales of $24.1 billion and adjusted EPS of $2.70, while raising its 2026 outlook to reported sales of $100.8 billion at the midpoint and adjusted EPS of $11.55. CEO Joaquin Duato described it as "a strong start to 2026." Talvey's latest data adds to a year already marked by multiple approvals and launches across pharmaceuticals and medtech.
However, bears argue that much of the good news may already be priced in. J&J shares traded at a price-to-earnings ratio of 27.9 on Friday. MarketBeat's analyst poll gives the stock a Moderate Buy rating with an average target price of $253.04, roughly 5% above current levels. Benzinga's consensus target is lower at $239.17, below Friday's close.
Legal risks remain a concern. Reuters reported on June 5 that J&J faces over 67,000 lawsuits alleging its baby powder and talc products caused ovarian cancer. While the company recently won a case in Los Angeles and has secured other victories, litigation overhang continues to weigh on the stock's multiple, raising questions about future payouts and investor sentiment.
The next major catalyst is the second-quarter earnings call scheduled for July 15 at 8:30 a.m. ET. Investors will focus on whether management maintains or raises its 2026 guidance, how it navigates Stelara's decline, and whether oncology and medtech growth remains robust. Any updates on timelines for new data-supported combinations will also be closely watched.
At current levels, J&J appears fairly valued, supported by solid growth drivers, promising oncology results, and a steady dividend. Yet the stock's pricing leaves little room for error if earnings, pipeline progress, or talc litigation take a negative turn.
